Computational study on novel natural inhibitors targeting BCL2
Ideal lead compounds and candidate drugs with inhibitory effect on BCL2 were screened from ZINC database, which laid a foundation for drug development and compound improvement of drug treatment for diffuse large B-cell lymphoma (DLCBL). Identification of potential BCL2 inhibitors by computer-aided v...
Gespeichert in:
| Veröffentlicht in: | Medical oncology (Northwood, London, England) London, England), 2021-08, Vol.38 (8), p.94, Article 94 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 8 |
| container_start_page | 94 |
| container_title | Medical oncology (Northwood, London, England) |
| container_volume | 38 |
| creator | Lv, Xiaye Jiang, Yuting Wang, Xinhui Xie, HaoQun Dou, Gaojing Wang, Jing Yang, Wenzhuo Wang, Hongyu Li, Zijian Zhang, Xiangheng Chen, Zhenghe |
| description | Ideal lead compounds and candidate drugs with inhibitory effect on BCL2 were screened from ZINC database, which laid a foundation for drug development and compound improvement of drug treatment for diffuse large B-cell lymphoma (DLCBL). Identification of potential BCL2 inhibitors by computer-aided virtual screening. Libdock was applied to 17,931 compounds and the top 20 were selected for further analysis. Selected compounds were performed absorption, distribution, metabolism, and excretion (ADME) and toxicity prediction. The binding affinity between the selected ligands and BCL2 was confirmed by Molecular docking. The new natural compounds, ZINC00000255131 and ZINC00013298233, were found to bind closely with BCL2. Furthermore, they all scored lower in ames-induced mutagenicity, rodent carcinogenicity, non-developmental toxicity potential, and cytochrome P4502D6 tolerance. Molecular dynamics simulation shows that the combinations of ZINC00000255131 and ZINC00013298233 with BCL2 in the natural environment are more stable. Two new compounds, ZINC00000255131 and ZINC00013298233, were found to be potential inhibitors of BCL2. These compounds have been proved to be safe, which is of great significance for the development and improvement of DLCBL drugs. |
| doi_str_mv | 10.1007/s12032-021-01513-x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2551416655</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2551416655</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-3bff90a7e978c542d7d358f9733792193928f369a6528a29b6a3bfc34b15fd93</originalsourceid><addsrcrecordid>eNqNkctO5DAQRS0EAgb4gVmMIrFEgfIrjjdIQ8QAUktsWMzOchKnMeq2e2yHx99jCNPABrFyyT636tY1Qj8xHGMAcRIxAUpKILgEzDEtHzfQLuZclpjiv5u5plyUwCvYQT9ivINMciK30Q5lhEtJ2S46bfxyNSadrHd6UcQ09k-Fd4Xz92ZROJ3GkK-tu7WtTT7EIukwN8m6eXHWzMg-2hr0IpqDt3MP3fw5v2kuy9n1xVXze1Z2TLBU0nYYJGhhpKg7zkgvesrrQQpKhSRYUknqgVZSV5zUmsi20lnSUdZiPvSS7qHTqe1qbJem74xL2ZZaBbvU4Ul5bdXnF2dv1dzfq5rUAJjlBodvDYL_N5qY1J0fQ944KsI5ZriqOM8Umagu-BiDGdYTMKiXyNUUucpBqtfI1WMW_frobS35n3EGjibgwbR-iJ01rjNrDAAqwV7YXAHOdP19urHTzzV-dClL6SSNGXdzE96X_ML_Mzc1rac</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2551416655</pqid></control><display><type>article</type><title>Computational study on novel natural inhibitors targeting BCL2</title><source>MEDLINE</source><source>SpringerNature Journals</source><source>Web of Science - Science Citation Index Expanded - 2021<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /></source><creator>Lv, Xiaye ; Jiang, Yuting ; Wang, Xinhui ; Xie, HaoQun ; Dou, Gaojing ; Wang, Jing ; Yang, Wenzhuo ; Wang, Hongyu ; Li, Zijian ; Zhang, Xiangheng ; Chen, Zhenghe</creator><creatorcontrib>Lv, Xiaye ; Jiang, Yuting ; Wang, Xinhui ; Xie, HaoQun ; Dou, Gaojing ; Wang, Jing ; Yang, Wenzhuo ; Wang, Hongyu ; Li, Zijian ; Zhang, Xiangheng ; Chen, Zhenghe</creatorcontrib><description>Ideal lead compounds and candidate drugs with inhibitory effect on BCL2 were screened from ZINC database, which laid a foundation for drug development and compound improvement of drug treatment for diffuse large B-cell lymphoma (DLCBL). Identification of potential BCL2 inhibitors by computer-aided virtual screening. Libdock was applied to 17,931 compounds and the top 20 were selected for further analysis. Selected compounds were performed absorption, distribution, metabolism, and excretion (ADME) and toxicity prediction. The binding affinity between the selected ligands and BCL2 was confirmed by Molecular docking. The new natural compounds, ZINC00000255131 and ZINC00013298233, were found to bind closely with BCL2. Furthermore, they all scored lower in ames-induced mutagenicity, rodent carcinogenicity, non-developmental toxicity potential, and cytochrome P4502D6 tolerance. Molecular dynamics simulation shows that the combinations of ZINC00000255131 and ZINC00013298233 with BCL2 in the natural environment are more stable. Two new compounds, ZINC00000255131 and ZINC00013298233, were found to be potential inhibitors of BCL2. These compounds have been proved to be safe, which is of great significance for the development and improvement of DLCBL drugs.</description><identifier>ISSN: 1357-0560</identifier><identifier>EISSN: 1559-131X</identifier><identifier>DOI: 10.1007/s12032-021-01513-x</identifier><identifier>PMID: 34259934</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject><![CDATA[Antineoplastic Agents - administration & dosage ; Apoptosis ; Binding sites ; Biological Products - administration & dosage ; Biological Products - metabolism ; Cancer therapies ; Computer Simulation ; Crystal structure ; Cytochrome ; Drug Delivery Systems - methods ; Drug development ; Drug Evaluation, Preclinical - methods ; Drugs ; Hematology ; Humans ; Internal Medicine ; Laboratories ; Life Sciences & Biomedicine ; Ligands ; Lymphoma ; Lymphoma, Large B-Cell, Diffuse - drug therapy ; Lymphoma, Large B-Cell, Diffuse - metabolism ; Medical prognosis ; Medicine ; Medicine & Public Health ; Metabolism ; Molecular Docking Simulation - methods ; Molecular Dynamics Simulation ; Oncology ; Original Paper ; Pathology ; Protein Structure, Secondary ; Protein Structure, Tertiary ; Proteins ; Proto-Oncogene Proteins c-bcl-2 - antagonists & inhibitors ; Proto-Oncogene Proteins c-bcl-2 - metabolism ; Science & Technology ; Simulation ; Software]]></subject><ispartof>Medical oncology (Northwood, London, England), 2021-08, Vol.38 (8), p.94, Article 94</ispartof><rights>The Author(s) 2021</rights><rights>2021. The Author(s).</rights><rights>The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>3</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000674425900001</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-c474t-3bff90a7e978c542d7d358f9733792193928f369a6528a29b6a3bfc34b15fd93</citedby><cites>FETCH-LOGICAL-c474t-3bff90a7e978c542d7d358f9733792193928f369a6528a29b6a3bfc34b15fd93</cites><orcidid>0000-0002-6161-9224</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12032-021-01513-x$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12032-021-01513-x$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,315,782,786,887,27933,27934,39267,41497,42566,51328</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34259934$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lv, Xiaye</creatorcontrib><creatorcontrib>Jiang, Yuting</creatorcontrib><creatorcontrib>Wang, Xinhui</creatorcontrib><creatorcontrib>Xie, HaoQun</creatorcontrib><creatorcontrib>Dou, Gaojing</creatorcontrib><creatorcontrib>Wang, Jing</creatorcontrib><creatorcontrib>Yang, Wenzhuo</creatorcontrib><creatorcontrib>Wang, Hongyu</creatorcontrib><creatorcontrib>Li, Zijian</creatorcontrib><creatorcontrib>Zhang, Xiangheng</creatorcontrib><creatorcontrib>Chen, Zhenghe</creatorcontrib><title>Computational study on novel natural inhibitors targeting BCL2</title><title>Medical oncology (Northwood, London, England)</title><addtitle>Med Oncol</addtitle><addtitle>MED ONCOL</addtitle><addtitle>Med Oncol</addtitle><description>Ideal lead compounds and candidate drugs with inhibitory effect on BCL2 were screened from ZINC database, which laid a foundation for drug development and compound improvement of drug treatment for diffuse large B-cell lymphoma (DLCBL). Identification of potential BCL2 inhibitors by computer-aided virtual screening. Libdock was applied to 17,931 compounds and the top 20 were selected for further analysis. Selected compounds were performed absorption, distribution, metabolism, and excretion (ADME) and toxicity prediction. The binding affinity between the selected ligands and BCL2 was confirmed by Molecular docking. The new natural compounds, ZINC00000255131 and ZINC00013298233, were found to bind closely with BCL2. Furthermore, they all scored lower in ames-induced mutagenicity, rodent carcinogenicity, non-developmental toxicity potential, and cytochrome P4502D6 tolerance. Molecular dynamics simulation shows that the combinations of ZINC00000255131 and ZINC00013298233 with BCL2 in the natural environment are more stable. Two new compounds, ZINC00000255131 and ZINC00013298233, were found to be potential inhibitors of BCL2. These compounds have been proved to be safe, which is of great significance for the development and improvement of DLCBL drugs.</description><subject>Antineoplastic Agents - administration & dosage</subject><subject>Apoptosis</subject><subject>Binding sites</subject><subject>Biological Products - administration & dosage</subject><subject>Biological Products - metabolism</subject><subject>Cancer therapies</subject><subject>Computer Simulation</subject><subject>Crystal structure</subject><subject>Cytochrome</subject><subject>Drug Delivery Systems - methods</subject><subject>Drug development</subject><subject>Drug Evaluation, Preclinical - methods</subject><subject>Drugs</subject><subject>Hematology</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Laboratories</subject><subject>Life Sciences & Biomedicine</subject><subject>Ligands</subject><subject>Lymphoma</subject><subject>Lymphoma, Large B-Cell, Diffuse - drug therapy</subject><subject>Lymphoma, Large B-Cell, Diffuse - metabolism</subject><subject>Medical prognosis</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metabolism</subject><subject>Molecular Docking Simulation - methods</subject><subject>Molecular Dynamics Simulation</subject><subject>Oncology</subject><subject>Original Paper</subject><subject>Pathology</subject><subject>Protein Structure, Secondary</subject><subject>Protein Structure, Tertiary</subject><subject>Proteins</subject><subject>Proto-Oncogene Proteins c-bcl-2 - antagonists & inhibitors</subject><subject>Proto-Oncogene Proteins c-bcl-2 - metabolism</subject><subject>Science & Technology</subject><subject>Simulation</subject><subject>Software</subject><issn>1357-0560</issn><issn>1559-131X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>HGBXW</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqNkctO5DAQRS0EAgb4gVmMIrFEgfIrjjdIQ8QAUktsWMzOchKnMeq2e2yHx99jCNPABrFyyT636tY1Qj8xHGMAcRIxAUpKILgEzDEtHzfQLuZclpjiv5u5plyUwCvYQT9ivINMciK30Q5lhEtJ2S46bfxyNSadrHd6UcQ09k-Fd4Xz92ZROJ3GkK-tu7WtTT7EIukwN8m6eXHWzMg-2hr0IpqDt3MP3fw5v2kuy9n1xVXze1Z2TLBU0nYYJGhhpKg7zkgvesrrQQpKhSRYUknqgVZSV5zUmsi20lnSUdZiPvSS7qHTqe1qbJem74xL2ZZaBbvU4Ul5bdXnF2dv1dzfq5rUAJjlBodvDYL_N5qY1J0fQ944KsI5ZriqOM8Umagu-BiDGdYTMKiXyNUUucpBqtfI1WMW_frobS35n3EGjibgwbR-iJ01rjNrDAAqwV7YXAHOdP19urHTzzV-dClL6SSNGXdzE96X_ML_Mzc1rac</recordid><startdate>20210801</startdate><enddate>20210801</enddate><creator>Lv, Xiaye</creator><creator>Jiang, Yuting</creator><creator>Wang, Xinhui</creator><creator>Xie, HaoQun</creator><creator>Dou, Gaojing</creator><creator>Wang, Jing</creator><creator>Yang, Wenzhuo</creator><creator>Wang, Hongyu</creator><creator>Li, Zijian</creator><creator>Zhang, Xiangheng</creator><creator>Chen, Zhenghe</creator><general>Springer US</general><general>Humana Press Inc</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>BLEPL</scope><scope>DTL</scope><scope>HGBXW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-6161-9224</orcidid></search><sort><creationdate>20210801</creationdate><title>Computational study on novel natural inhibitors targeting BCL2</title><author>Lv, Xiaye ; Jiang, Yuting ; Wang, Xinhui ; Xie, HaoQun ; Dou, Gaojing ; Wang, Jing ; Yang, Wenzhuo ; Wang, Hongyu ; Li, Zijian ; Zhang, Xiangheng ; Chen, Zhenghe</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-3bff90a7e978c542d7d358f9733792193928f369a6528a29b6a3bfc34b15fd93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Antineoplastic Agents - administration & dosage</topic><topic>Apoptosis</topic><topic>Binding sites</topic><topic>Biological Products - administration & dosage</topic><topic>Biological Products - metabolism</topic><topic>Cancer therapies</topic><topic>Computer Simulation</topic><topic>Crystal structure</topic><topic>Cytochrome</topic><topic>Drug Delivery Systems - methods</topic><topic>Drug development</topic><topic>Drug Evaluation, Preclinical - methods</topic><topic>Drugs</topic><topic>Hematology</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Laboratories</topic><topic>Life Sciences & Biomedicine</topic><topic>Ligands</topic><topic>Lymphoma</topic><topic>Lymphoma, Large B-Cell, Diffuse - drug therapy</topic><topic>Lymphoma, Large B-Cell, Diffuse - metabolism</topic><topic>Medical prognosis</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metabolism</topic><topic>Molecular Docking Simulation - methods</topic><topic>Molecular Dynamics Simulation</topic><topic>Oncology</topic><topic>Original Paper</topic><topic>Pathology</topic><topic>Protein Structure, Secondary</topic><topic>Protein Structure, Tertiary</topic><topic>Proteins</topic><topic>Proto-Oncogene Proteins c-bcl-2 - antagonists & inhibitors</topic><topic>Proto-Oncogene Proteins c-bcl-2 - metabolism</topic><topic>Science & Technology</topic><topic>Simulation</topic><topic>Software</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lv, Xiaye</creatorcontrib><creatorcontrib>Jiang, Yuting</creatorcontrib><creatorcontrib>Wang, Xinhui</creatorcontrib><creatorcontrib>Xie, HaoQun</creatorcontrib><creatorcontrib>Dou, Gaojing</creatorcontrib><creatorcontrib>Wang, Jing</creatorcontrib><creatorcontrib>Yang, Wenzhuo</creatorcontrib><creatorcontrib>Wang, Hongyu</creatorcontrib><creatorcontrib>Li, Zijian</creatorcontrib><creatorcontrib>Zhang, Xiangheng</creatorcontrib><creatorcontrib>Chen, Zhenghe</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>Web of Science - Science Citation Index Expanded - 2021</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Medical oncology (Northwood, London, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lv, Xiaye</au><au>Jiang, Yuting</au><au>Wang, Xinhui</au><au>Xie, HaoQun</au><au>Dou, Gaojing</au><au>Wang, Jing</au><au>Yang, Wenzhuo</au><au>Wang, Hongyu</au><au>Li, Zijian</au><au>Zhang, Xiangheng</au><au>Chen, Zhenghe</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Computational study on novel natural inhibitors targeting BCL2</atitle><jtitle>Medical oncology (Northwood, London, England)</jtitle><stitle>Med Oncol</stitle><stitle>MED ONCOL</stitle><addtitle>Med Oncol</addtitle><date>2021-08-01</date><risdate>2021</risdate><volume>38</volume><issue>8</issue><spage>94</spage><pages>94-</pages><artnum>94</artnum><issn>1357-0560</issn><eissn>1559-131X</eissn><abstract>Ideal lead compounds and candidate drugs with inhibitory effect on BCL2 were screened from ZINC database, which laid a foundation for drug development and compound improvement of drug treatment for diffuse large B-cell lymphoma (DLCBL). Identification of potential BCL2 inhibitors by computer-aided virtual screening. Libdock was applied to 17,931 compounds and the top 20 were selected for further analysis. Selected compounds were performed absorption, distribution, metabolism, and excretion (ADME) and toxicity prediction. The binding affinity between the selected ligands and BCL2 was confirmed by Molecular docking. The new natural compounds, ZINC00000255131 and ZINC00013298233, were found to bind closely with BCL2. Furthermore, they all scored lower in ames-induced mutagenicity, rodent carcinogenicity, non-developmental toxicity potential, and cytochrome P4502D6 tolerance. Molecular dynamics simulation shows that the combinations of ZINC00000255131 and ZINC00013298233 with BCL2 in the natural environment are more stable. Two new compounds, ZINC00000255131 and ZINC00013298233, were found to be potential inhibitors of BCL2. These compounds have been proved to be safe, which is of great significance for the development and improvement of DLCBL drugs.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>34259934</pmid><doi>10.1007/s12032-021-01513-x</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0002-6161-9224</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1357-0560 |
| ispartof | Medical oncology (Northwood, London, England), 2021-08, Vol.38 (8), p.94, Article 94 |
| issn | 1357-0560 1559-131X |
| language | eng |
| recordid | cdi_proquest_journals_2551416655 |
| source | MEDLINE; SpringerNature Journals; Web of Science - Science Citation Index Expanded - 2021<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /> |
| subjects | Antineoplastic Agents - administration & dosage Apoptosis Binding sites Biological Products - administration & dosage Biological Products - metabolism Cancer therapies Computer Simulation Crystal structure Cytochrome Drug Delivery Systems - methods Drug development Drug Evaluation, Preclinical - methods Drugs Hematology Humans Internal Medicine Laboratories Life Sciences & Biomedicine Ligands Lymphoma Lymphoma, Large B-Cell, Diffuse - drug therapy Lymphoma, Large B-Cell, Diffuse - metabolism Medical prognosis Medicine Medicine & Public Health Metabolism Molecular Docking Simulation - methods Molecular Dynamics Simulation Oncology Original Paper Pathology Protein Structure, Secondary Protein Structure, Tertiary Proteins Proto-Oncogene Proteins c-bcl-2 - antagonists & inhibitors Proto-Oncogene Proteins c-bcl-2 - metabolism Science & Technology Simulation Software |
| title | Computational study on novel natural inhibitors targeting BCL2 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-03T08%3A05%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Computational%20study%20on%20novel%20natural%20inhibitors%20targeting%20BCL2&rft.jtitle=Medical%20oncology%20(Northwood,%20London,%20England)&rft.au=Lv,%20Xiaye&rft.date=2021-08-01&rft.volume=38&rft.issue=8&rft.spage=94&rft.pages=94-&rft.artnum=94&rft.issn=1357-0560&rft.eissn=1559-131X&rft_id=info:doi/10.1007/s12032-021-01513-x&rft_dat=%3Cproquest_cross%3E2551416655%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2551416655&rft_id=info:pmid/34259934&rfr_iscdi=true |